As of Thursday close, Vanda Pharmaceuticals Inc.’s (NASDAQ:VNDA) stock was up $0.18, moving up 4.21 percent to $4.46. The average number of shares traded per day over the past five days has been 4,598,380 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.29 fall in that time frame. In the last twenty days, the average volume was 2,243,970, while in the previous 50 days, it was 1,248,048.
Since last month, VNDA stock retreated -24.92%. Shares of the company fell to $4.15 on 09/05/23, the lowest level in the past month. A 52-week high of $11.04 was reached on 02/09/23 after having rallying from a 52-week low of $4.15. Since the beginning of this year, VNDA’s stock price has dropped by -39.65% or -$2.93, and marked a new high 7 times. However, the stock has declined by -59.61% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
VNDA stock investors should be aware that Vanda Pharmaceuticals Inc. (VNDA) stock had its last reported insider trading activity 32 days ago on Aug 21. Wijkstrom Joakim, the SVP, Chief Marketing Officer of the company, disposed of 3,724 shares for $5.84 on Aug 21. It resulted in a $21,748 divestment by the insider. Mitchell Stephen Ray sold 6,500 shares at an average price of $6.05 on Aug 10. The insider now owns 29,328 shares following the transaction. On Jul 28, SVP, CFO & Treasurer Moran Kevin Patrick sold 2,212 shares at $6.30 apiece. The transaction was valued at $13,945.
Valuation Metrics
Right now, Vanda Pharmaceuticals Inc. (VNDA) has a P/E ratio of about 17.35. The stock’s beta is 0.73. Besides these, the trailing price-to-sales (P/S) ratio of 1.09, the price-to-book (PB) ratio of 0.47, and the price-to-cash flow ratio of 6.43 may also be considered.
Financial Health
In the three months ended June 29, Vanda Pharmaceuticals Inc.’s quick ratio stood at 6.10, while its current ratio was 6.10, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 91.30% percent. In the year ended June 29, EBITDA margin amounted to 3.56%, whereas operating margins totaled 4.10%. Based on annual data, VNDA earned $230.1 million in gross profit and brought in $254.38 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 0.20%. Return on equity (ROE) for the past 12 months was 2.80%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. VNDA’s revenue fell -39.8% to $62.5 million during the quarter, while net income inched up to $46.06 million. While analysts expected Vanda Pharmaceuticals Inc. to report -$0.13 quarterly earnings, the actual figure was $0.03 per share, beating the consensus estimate by 123.10%. During the quarter, the company generated -$4.22 million in EBITDA. The liabilities of Vanda Pharmaceuticals Inc. were 101.78 million at the end of its most recent quarter ended June 29, and its total debt was $10.31 million. The value of shareholders’ equity is $57.51 million.
Technical Picture
This quick technical analysis looks at Vanda Pharmaceuticals Inc.’s (VNDA) price momentum. With a historical volatility rate of 40.68%, the RSI 9-day stood at 33.60% on 21 September.
With respect to its five-day moving average, the current Vanda Pharmaceuticals Inc. price is down by -6.11% percent or -$0.29. At present, VNDA shares trade -24.28% below its 20-day simple moving average and -27.36% percent below its 100-day simple moving average. However, the stock is currently trading approximately -28.53% below its SMA50 and -59.12% below its SMA200.
Stochastic coefficient K was 17.95% and Stochastic coefficient D was 20.00%, while ATR was 0.24. Given the Stochastic reading of 25.73% for the 14-day period, the RSI (14) reading has been calculated as 31.85%. As of today, the MACD Oscillator reading stands at -0.19, while the 14-day reading stands at -0.22.
Analyst Ratings
Vanda Pharmaceuticals Inc. downgraded its rating on Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) to a Hold in a note to investors on February 25, 2022. The analysts firm previously had a Buy rating on the stock.Vanda Pharmaceuticals Inc. (VNDA) has been rated Hold by analysts. According to 0 brokerage firms, VNDA is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Vanda Pharmaceuticals Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $7.00, the current consensus forecast for the stock is $7.00 – $7.00. Based on these forecasts, analysts predict Vanda Pharmaceuticals Inc. (VNDA) will achieve an average price target of $7.00.
